Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories
15th National Conference of the IAOMFP, Chennai, 2006
Abstract
Abstracts from current literature
Acne in India: Guidelines for management - IAA Consensus Document
Addendum
Announcement
Art & Psychiatry
Article
Articles
Association Activities
Association Notes
Award Article
Book Review
Brief Report
Case Analysis
Case Letter
Case Letters
Case Notes
Case Report
Case Reports
Clinical and Laboratory Investigations
Clinical Article
Clinical Studies
Clinical Study
Commentary
Conference Oration
Conference Summary
Continuing Medical Education
Correspondence
Corrigendum
Cosmetic Dermatology
Cosmetology
Current Best Evidence
Current View
Derma Quest
Dermato Surgery
Dermatopathology
Dermatosurgery Specials
Dispensing Pearl
Do you know?
Drug Dialogues
e-IJDVL
Editor Speaks
Editorial
Editorial Remarks
Editorial Report
Editorial Report - 2007
Editorial report for 2004-2005
Errata
Erratum
Focus
Fourth All India Conference Programme
From Our Book Shelf
From the Desk of Chief Editor
General
Get Set for Net
Get set for the net
Guest Article
Guest Editorial
History
How I Manage?
IADVL Announcement
IADVL Announcements
IJDVL Awards
IJDVL AWARDS 2015
IJDVL Awards 2018
IJDVL Awards 2019
IJDVL International Awards 2018
Images in Clinical Practice
In Memorium
Inaugural Address
Index
Knowledge From World Contemporaries
Leprosy Section
Letter in Response to Previous Publication
Letter to Editor
Letter to the Editor
Letter to the Editor - Case Letter
Letter to the Editor - Letter in Response to Published Article
LETTER TO THE EDITOR - LETTERS IN RESPONSE TO PUBLISHED ARTICLES
Letter to the Editor - Observation Letter
Letter to the Editor - Study Letter
Letter to the Editor - Therapy Letter
Letter to the Editor: Articles in Response to Previously Published Articles
Letters to the Editor
Letters to the Editor - Letter in Response to Previously Published Articles
Letters to the Editor: Case Letters
Letters to the Editor: Letters in Response to Previously Published Articles
Medicolegal Window
Messages
Miscellaneous Letter
Musings
Net Case
Net case report
Net Image
Net Letter
Net Quiz
Net Study
New Preparations
News
News & Views
Obituary
Observation Letter
Observation Letters
Oration
Original Article
ORIGINAL CONTRIBUTION
Original Contributions
Pattern of Skin Diseases
Pearls
Pediatric Dermatology
Pediatric Rounds
Perspective
Presedential Address
Presidential Address
Presidents Remarks
Quiz
Recommendations
Regret
Report
Report of chief editor
Report of Hon : Treasurer IADVL
Report of Hon. General Secretary IADVL
Research Methdology
Research Methodology
Resident page
Resident's Page
Resident’s Page
Residents' Corner
Residents' Corner
Residents' Page
Retraction
Review
Review Article
Review Articles
Revision Corner
Self Assessment Programme
SEMINAR
Seminar: Chronic Arsenicosis in India
Seminar: HIV Infection
Short Communication
Short Communications
Short Report
Special Article
Specialty Interface
Studies
Study Letter
Supplement-Photoprotection
Supplement-Psoriasis
Symposium - Contact Dermatitis
Symposium - Lasers
Symposium - Pediatric Dermatoses
Symposium - Psoriasis
Symposium - Vesicobullous Disorders
SYMPOSIUM - VITILIGO
Symposium Aesthetic Surgery
Symposium Dermatopathology
Symposium-Hair Disorders
Symposium-Nails Part I
Symposium-Nails-Part II
Tables
Technology
Therapeutic Guidelines
Therapeutic Guidelines - IADVL
Therapeutics
Therapy
Therapy Letter
View Point
Viewpoint
What’s new in Dermatology
View/Download PDF
Letter To Editor
2008:74:6;675-676
doi: 10.4103/0378-6323.45131
PMID: 19172012

Aggravation of psoriasis by antimalarials: A comment on the pathogenic mechanism

MR Namazi
 Department of Dermatology, Shiraz University of Medical Sciences, Shiraz, Iran

Correspondence Address:
M R Namazi
Dermatology Department, Faghihi Hospital, Shiraz
Iran
How to cite this article:
Namazi M R. Aggravation of psoriasis by antimalarials: A comment on the pathogenic mechanism. Indian J Dermatol Venereol Leprol 2008;74:675-676
Copyright: (C)2008 Indian Journal of Dermatology, Venereology, and Leprology

Sir,

Exacerbation of psoriasis in patients taking antimalarials is mentioned in all dermatology textbooks, but the underlying mechanism has not been explained in full. It is estimated that up to 18% of patients with psoriasis would develop an exacerbation of their disease following antimalarial therapy. In contrast to lithium and beta blockers, antimalarials do not induce psoriasis de novo, but they only trigger already existing psoriasis, via a pharmacologic mechanism, probably due to an alteration of the activity of enzymes involved in the epidermal proliferation process. Wolf et al. [1] have shown that hydroxychloroquine inhibited transglutaminase activity in a concentration-dependent manner. This is suggested to cause an initial break in the barrier function of the epidermis, followed by a physiologic response of the epidermis aimed at barrier restoration. This rather nonspecific stimulus to epidermal proliferation is suggested to be sufficient to trigger psoriasis in predisposed individuals. That antimalarial drugs only trigger latent psoriasis and do not induce psoriasis de novo can be suspected from the fact that psoriasis cleared up completely after withdrawal of the drug in only 30% of patients on antimalarials, as compared with more than 60% of those receiving lithium and nearly 50% of those receiving beta blockers. This is probably also why the incubation period of the cases induced by antimalarial drugs is much shorter than that of the cases induced by lithium and beta blockers. Possibly, in triggered psoriasis (as in antimalarials), the drug only sets off with a chain of pathologic events previously programmed and ready to be set off; whereas in true drug-induced cases (as in some cases induced by lithium and beta blockers), the drug is supposed to cause more profound changes and therefore more time is needed for these changes to occur. [1],[2]

Herein, I would like to suggest that antimalarials′ induction of psoriasis could be partly attributed to their inhibition of cholesterol biosynthesis as well.

Cholesterol biosynthesis by keratinocytes is documented to be fundamental to the integrity of epidermal barrier function. It is shown that topical application of lovastatin to the skin of hairless mice led to the development of epidermal hyperplasia, erythema, scaling, and increased DNA synthesis. This effect, being secondary to the disruption of skin barrier as the result of decreased production of cholesterol by keratinocytes, was aborted with concomitant application of cholesterol. [3]

An important point needing attention is that though topically induced statins induce epidermal barrier dysfunction, the risk of exacerbation of psoriasis with orally administered statins is extremely low. In fact, it has been shown that pharmacologic doses of lovastatin do not worsen the course of psoriasis; and though gemfibrozil, an anti-triglyceride agent, has been reported to exacerbate psoriasis, statins have not been reported to do so; and even the lovastatin manufacturer (Merck Sharp and Dome, Rahway, NJ, USA) has anecdotal evidence that the condition of some psoriatic subjects improves when this drug is administered. It is most likely that the beneficial immunomodulatory effects of statins on immunocytes outweigh their untoward effect on surface lipids or they have not enough bioavailability to keratinocytes to affect keratinocytic cholesterol synthesis.[4]

There are several reports of aggravation of psoriasis with terbinafine, which is explained by the ability of this agent to inhibit squalene epoxidase, a pivotal enzyme in mammalian cholesterol biosynthesis. [5]

Interestingly, both chloroquine and hydroxychloroquine are reported to significantly decrease serum cholesterol levels, hence neutralizing the dyslipidemia seen in systemic lupus erythematosus patients taking steroids. [6],[7] Chloroquine is shown to be a potent inhibitor of cholesterol biosynthesis by isolated rat hepatocytes. It does not affect fatty acid synthesis by isolated hepatocytes, suggesting that it acts on the cholesterol biosynthetic pathway beyond the cytosolic acetyl-coA branch-point of cholesterol and fatty acid synthesis. [8]

Therefore, it could be deduced that antimalarials′ inhibition of cholesterol biosynthesis contributes to the epidermal barrier dysfunction induced by their transglutaminase inhibition, which can exacerbate psoriasis in genetically predisposed individuals by triggering epidermal hyperproliferation. This dual mechanism explains the relatively high incidence of aggravation of psoriasis by these agents, which has attracted the attention of all authors of dermatology textbooks.

References
1.
Wolf R, Ruocco V. Triggered psoriasis. Adv Exp Med Biol 1999;455:221-5.
[Google Scholar]
2.
Wolf R, Schiavo AL, Lombardi ML, de Angelis F, Ruocco V. The in vitro effect of hydroxychloroquine on skin morphology in psoriasis. Int J Dermatol 1999;38:154-7.
[Google Scholar]
3.
FeingoldK R, Mac-QiangM, PredschE, MenonG K, BrownB E, EliasP M. The lovastatin-treated rodent: A new model of barrier disruption and epidermal hyperplasia. J Invest Dermatol 1991;96:201-9.
[Google Scholar]
4.
Namazi MR. Statins: Novel additions to the dermatologic arsenal? Exp Dermatol 2004;13:337-9.
[Google Scholar]
5.
Szepietowski JC. Terbinafine exacerbates psoriasis: Case report with a literature review. Acta Dermatovenerol Croat 2003;11:17-21.
[Google Scholar]
6.
Ardoin SP, Sandborg C, Schanberg LE. Management of dyslipidemia in children and adolescents with systemic lupus erythematosus. Lupus 2007;16:618-26.
[Google Scholar]
7.
Wo?niacka A, Lesiak A, Smigielski J, Sysa-Jedrzejowska A. Chloroquine influence on lipid metabolism and selected laboratory parameters. Przegl Lek 2005;62:855-9.
[Google Scholar]
8.
Beynen AC, van der Molen AJ, Geelen MJ. Inhibition of hepatic cholesterol biosynthesis by chloroquine. Lipids 1981;16:472-4.
[Google Scholar]

Fulltext Views
56

PDF downloads
8
Show Sections